Please use this identifier to cite or link to this item: https://doi.org/10.1038/ncomms13131
DC FieldValue
dc.titleMolecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets
dc.contributor.authorChen, Y.-B
dc.contributor.authorXu, J
dc.contributor.authorSkanderup, A.J
dc.contributor.authorDong, Y
dc.contributor.authorBrannon, A.R
dc.contributor.authorWang, L
dc.contributor.authorWon, H.H
dc.contributor.authorWang, P.I
dc.contributor.authorNanjangud, G.J
dc.contributor.authorJungbluth, A.A
dc.contributor.authorLi, W
dc.contributor.authorOjeda, V
dc.contributor.authorHakimi, A.A
dc.contributor.authorVoss, M.H
dc.contributor.authorSchultz, N
dc.contributor.authorMotzer, R.J
dc.contributor.authorRusso, P
dc.contributor.authorCheng, E.H
dc.contributor.authorGiancotti, F.G
dc.contributor.authorLee, W
dc.contributor.authorBerger, M.F
dc.contributor.authorTickoo, S.K
dc.contributor.authorReuter, V.E
dc.contributor.authorHsieh, J.J
dc.date.accessioned2020-10-26T03:09:34Z
dc.date.available2020-10-26T03:09:34Z
dc.date.issued2016
dc.identifier.citationChen, Y.-B, Xu, J, Skanderup, A.J, Dong, Y, Brannon, A.R, Wang, L, Won, H.H, Wang, P.I, Nanjangud, G.J, Jungbluth, A.A, Li, W, Ojeda, V, Hakimi, A.A, Voss, M.H, Schultz, N, Motzer, R.J, Russo, P, Cheng, E.H, Giancotti, F.G, Lee, W, Berger, M.F, Tickoo, S.K, Reuter, V.E, Hsieh, J.J (2016). Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature Communications 7 : 13131. ScholarBank@NUS Repository. https://doi.org/10.1038/ncomms13131
dc.identifier.issn2041-1723
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/179799
dc.description.abstractRenal cell carcinomas with unclassified histology (uRCC) constitute a significant portion of aggressive non-clear cell renal cell carcinomas that have no standard therapy. The oncogenic drivers in these tumours are unknown. Here we perform a molecular analysis of 62 high-grade primary uRCC, incorporating targeted cancer gene sequencing, RNA sequencing, single-nucleotide polymorphism array, fluorescence in situ hybridization, immunohistochemistry and cell-based assays. We identify recurrent somatic mutations in 29 genes, including NF2 (18%), SETD2 (18%), BAP1 (13%), KMT2C (10%) and MTOR (8%). Integrated analysis reveals a subset of 26% uRCC characterized by NF2 loss, dysregulated Hippo-YAP pathway and worse survival, whereas 21% uRCC with mutations of MTOR, TSC1, TSC2 or PTEN and hyperactive mTORC1 signalling are associated with better clinical outcome. FH deficiency (6%), chromatin/DNA damage regulator mutations (21%) and ALK translocation (2%) distinguish additional cases. Altogether, this study reveals distinct molecular subsets for 76% of our uRCC cohort, which could have diagnostic and therapeutic implications. © The Author(s) 2016.
dc.publisherNature Publishing Group
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectBAP1 protein
dc.subjectDNA
dc.subjectKMT2C protein
dc.subjectmammalian target of rapamycin
dc.subjectmammalian target of rapamycin complex 1
dc.subjectmerlin
dc.subjectoncoprotein
dc.subjectphosphatidylinositol 3,4,5 trisphosphate 3 phosphatase
dc.subjectRNA
dc.subjectSETD2 protein
dc.subjectTSC1 protein
dc.subjecttuberin
dc.subjectunclassified drug
dc.subjectBAP1 protein, human
dc.subjecthistone lysine methyltransferase
dc.subjectMTOR protein, human
dc.subjectSet2 protein, human
dc.subjecttarget of rapamycin kinase
dc.subjecttumor protein
dc.subjecttumor suppressor protein
dc.subjectubiquitin thiolesterase
dc.subjectbioassay
dc.subjectcancer
dc.subjectcells and cell components
dc.subjectgene expression
dc.subjectgenetic analysis
dc.subjectgenetic marker
dc.subjecthistology
dc.subjectmolecular analysis
dc.subjectmutation
dc.subjectprotein
dc.subjecttumor
dc.subjectArticle
dc.subjectcancer genetics
dc.subjectcancer survival
dc.subjectcarcinogenesis
dc.subjectcell assay
dc.subjectchromatin
dc.subjectclinical outcome
dc.subjectcontrolled study
dc.subjectDNA damage
dc.subjectfluorescence in situ hybridization
dc.subjectgene expression
dc.subjectgermline mutation
dc.subjecthistology
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman tissue
dc.subjectimmunohistochemistry
dc.subjectkidney carcinoma
dc.subjectmolecular genetics
dc.subjectnucleotide sequence
dc.subjectRNA sequence
dc.subjectsignal transduction
dc.subjectsingle nucleotide polymorphism
dc.subjectsomatic mutation
dc.subjecttumor gene
dc.subjectgenetics
dc.subjectHEK293 cell line
dc.subjectkidney tumor
dc.subjectneurofibromatosis type 2
dc.subjectpathology
dc.subjectrenal cell carcinoma
dc.subjecttumor cell line
dc.subjectCarcinoma, Renal Cell
dc.subjectCell Line, Tumor
dc.subjectDNA Damage
dc.subjectHEK293 Cells
dc.subjectHistone-Lysine N-Methyltransferase
dc.subjectHumans
dc.subjectIn Situ Hybridization, Fluorescence
dc.subjectKidney Neoplasms
dc.subjectNeoplasm Proteins
dc.subjectNeurofibromatosis 2
dc.subjectPolymorphism, Single Nucleotide
dc.subjectSignal Transduction
dc.subjectTOR Serine-Threonine Kinases
dc.subjectTumor Suppressor Proteins
dc.subjectUbiquitin Thiolesterase
dc.typeArticle
dc.contributor.departmentDEPARTMENT OF COMPUTER SCIENCE
dc.description.doi10.1038/ncomms13131
dc.description.sourcetitleNature Communications
dc.description.volume7
dc.description.page13131
dc.published.statepublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_ncomms13131.pdf897.11 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons